<DOC>
	<DOCNO>NCT00657189</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability multiple dose MEDI-545 subject moderately severely active Lupus .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Subcutaneous Doses MEDI-545 Subjects With Lupus</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability multiple SC dose MEDI-545 subject ≥ 18 year age moderately severely active SLE despite standard care .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female subject ≥ 18 year time first dose study drug ; Written inform consent HIPAA authorization ( applies cover entity US ) obtain subject subject 's legal representative ; Meet least 4 11 revise ACR classification criterion SLE Have positive antinuclear antibody test ( ANA ) ≥ 1:80 serum dilution document past screening ; Have least 1 system score A 2 system score B BILAG index screening , SELENASLEDAI score ≥ 6 ; Treatment SLE antimalarial , oral prednisone another systemic corticosteroid , mycophenolate mofetil , methotrexate , leflunomide , azathioprine , dapsone ; Women , unless surgically sterile least 2 year postmenopausal , must use effective method avoid pregnancy ( include oral , injectable , transdermal , implanted contraceptive , intrauterine device , diaphragm spermicide , cervical cap , abstinence , sterile sexual partner ) addition use condom ( male female condom spermicide ) screen end study . Cessation birth control point discuss responsible physician . Men unless surgically sterile , must likewise practice 2 effective method birth control ( condom spermicide abstinence ) Study Day 0 end study ; Ability complete study period , include followup period Study Day 168 ; Willing forego form experimental treatment study . Have receive MEDI545 within 120 day prior screen ; History allergy reaction component study drug formulation ; Have receive following medication within 28 day randomization : Systemic cyclophosphamide dose Cyclosporine dose Thalidomide dose Hydroxychloroquine &gt; 600 mg/day Mycophenolate mofetil &gt; 3 g/day Methotrexate &gt; 25 mg/week Azathioprine &gt; 3 mg/kg/day Have receive fluctuating dos follow within 28 day randomization : Antimalarials Mycophenolate mofetil Methotrexate Leflunomide Azathioprine Dapsone Have receive Leflunomide &gt; 20mg/day 6 month prior Study Day 0 ; Have receive prednisone &gt; 20 mg/day fluctuating dos within 14 day randomization ; Have receive fluctuating dos nonsteroidal antiinflammatory drug within 14 day randomization ; Treatment investigational drug therapy within 28 day randomization study , B celldepleting therapy within 12 month randomization , biologic therapy within 30 day 5 halflives biologic agent , whichever longer , randomization study ; In investigator 's opinion , evidence clinically significant active infection , include ongoing , chronic infection , within 28 day randomization ; A history severe viral infection judge investigator , include severe infection either cytomegalovirus herpes family disseminate herpes , herpes encephalitis , ophthalmic herpes ; Herpes zoster infection within 3 month randomization ; Evidence infection hepatitis B C virus , human immunodeficiency virus ( HIV ) 1 HIV2 , active infection hepatitis A , determined result test screen Vaccination live attenuate virus within 28 day randomization ; Pregnancy ( woman , unless surgically sterile least 2 year postmenopausal , must negative serum pregnancy test within 28 day receive study drug negative urine pregnancy test day study drug administration receive study drug ) ; Breastfeeding lactate woman ; History primary immunodeficiency ; History alcohol drug abuse &lt; 1 year prior randomization ; History cancer ( except basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy &gt; 1 year prior randomization ) ; History active tuberculosis ( TB ) infection newly positive TB skin test ( define reaction ≥ 10 mm diameter systemic immunosuppressive medication ≥ 5 mm systemic immunosuppressive medication ; History latent TB infection without completion appropriate course treatment ; Elective surgery plan time screen Study Day 168 ; At screen blood test ( within 28 day randomization ) , follow : AST &gt; 2.5 x upper limit normal range ( ULN ) , unless cause SLE ALT &gt; 2.5 x ULN , unless cause SLE Creatinine &gt; 4.0 mg/dL Neutrophils &lt; 1,500/mm3 Platelet count &lt; 50,000/mm3 History disease , evidence current disease ( SLE ) , find upon physical examination , laboratory abnormality , opinion investigator medical monitor , may compromise safety subject study confound analysis study ; Any employee research site involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sifalimumab</keyword>
	<keyword>MEDI-545</keyword>
	<keyword>Lupus erythematosus , systemic</keyword>
</DOC>